-
Je něco špatně v tomto záznamu ?
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group
F. Sclafani, E. Fontana, L. Wyrwicz, AD. Wagner, JW. Valle, E. Smyth, M. Peeters, R. Obermannova, C. Neuzillet, MP. Lutz, T. Koessler, I. Ben-Aharon, D. Arnold, M. Alsina, M. Moehler
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy, práce podpořená grantem
- MeSH
- COVID-19 * MeSH
- gastrointestinální nádory * diagnóza genetika terapie MeSH
- lékařská onkologie MeSH
- lidé MeSH
- pandemie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients' needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.
Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital Cambridge UK
Caritasklinikum Saarbrucken Germany
Department of Internal Medicine Johannes Gutenberg University Mainz Germany
Department of Medical Oncology Institut Jules Bordet Rue Meylemeersch 90 Anderlecht 1070 Belgium
Department of Medical Oncology The Christie NHS Foundation Trust Manchester UK
Department of Oncology Geneva University Hospital Geneva Switzerland
Department of Oncology Universitair Ziekenhuis Antwerpen Antwerp Belgium
Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic
Division of Cancer Sciences University of Manchester Manchester UK
Division of Oncology Rambam Health Care Campus Rappaport Faculty of Medicine Technion Haifa Israel
European Organisation for Research and Treatment of Cancer Brussel Belgium
Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology Warsaw Poland
Sarah Cannon Research Institute London UK
Swiss Cancer Center Leman University of Geneva Lausanne Switzerland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024532
- 003
- CZ-PrNML
- 005
- 20221031100929.0
- 007
- ta
- 008
- 221017s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clcc.2022.04.001 $2 doi
- 035 __
- $a (PubMed)35637095
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Sclafani, Francesco $u Department of Medical Oncology, Institut Jules Bordet, Rue Meylemeersch 90, Anderlecht 1070, Belgium; Université Libre de Bruxelles (ULB), Brussels, Belgium; European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Electronic address: francesco.sclafani@bordet.be
- 245 10
- $a Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group / $c F. Sclafani, E. Fontana, L. Wyrwicz, AD. Wagner, JW. Valle, E. Smyth, M. Peeters, R. Obermannova, C. Neuzillet, MP. Lutz, T. Koessler, I. Ben-Aharon, D. Arnold, M. Alsina, M. Moehler
- 520 9_
- $a Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients' needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.
- 650 12
- $a COVID-19 $7 D000086382
- 650 12
- $a gastrointestinální nádory $x diagnóza $x genetika $x terapie $7 D005770
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lékařská onkologie $7 D008495
- 650 _2
- $a pandemie $7 D058873
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Fontana, Elisa $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Sarah Cannon Research Institute, London, UK
- 700 1_
- $a Wyrwicz, Lucjan $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Wagner, Anna Dorothea $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Oncology, Division of medical Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
- 700 1_
- $a Valle, Juan W $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
- 700 1_
- $a Smyth, Elizabeth $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK
- 700 1_
- $a Peeters, Mark $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Oncology, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
- 700 1_
- $a Obermannova, Radka $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Neuzillet, Cindy $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Medical Oncology, Institut Curie, Versailles Saint-Quentin University - Paris Saclay University, Saint-Cloud, France
- 700 1_
- $a Lutz, Manfred P $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Caritasklinikum, Saarbrucken, Germany
- 700 1_
- $a Koessler, Thibaud $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Oncology, Geneva University Hospital, Geneva, Switzerland; Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland
- 700 1_
- $a Ben-Aharon, Irit $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel
- 700 1_
- $a Arnold, Dirk $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Oncology, Haematology and Palliative Care, AK Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany
- 700 1_
- $a Alsina, Maria $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, Barcelona, Spain
- 700 1_
- $a Moehler, Markus $u European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Internal Medicine, Johannes-Gutenberg University, Mainz, Germany
- 773 0_
- $w MED00007435 $t Clinical colorectal cancer $x 1938-0674 $g Roč. 21, č. 3 (2022), s. 188-197
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35637095 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100926 $b ABA008
- 999 __
- $a ok $b bmc $g 1854319 $s 1175822
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 21 $c 3 $d 188-197 $e 20220425 $i 1938-0674 $m Clinical colorectal cancer $n Clin Colorectal Cancer $x MED00007435
- LZP __
- $a Pubmed-20221017
